sunitinib viasana
viasana, uab - sunitinibas - kietosios kapsulės - 25 mg - sunitinib
sunitinib viasana
viasana, uab - sunitinibas - kietosios kapsulės - 50 mg - sunitinib
ikelan
medochemie ltd. - atenololis - plėvele dengtos tabletės - 50 mg - atenolol
ibuprofen nvt
nvt, uab - ibuprofenas - minkštosios kapsulės - 400 mg - ibuprofen
morphine hydrochloride kalceks
as kalceks - morfino hidrochloridas - injekcinis tirpalas - 10 mg/ml - morphine
anefaltic
sanoswiss, uab - nefopamo hidrochloridas - plėvele dengtos tabletės - 30 mg - nefopam
agranin
ibe pharma, uab - acetilsalicilo rūgštis/paracetamolis/kofeinas - tabletės - 250 mg/250 mg/65 mg - acetylsalicylic acid, comb. with psycholeptics
losartan potassium stada
stada arzneimittel ag - losartano kalio druska - plėvele dengtos tabletės - 100 mg - losartan
galiron [licaformot]
septinta s.p.r.l. - formoterolio fumaratas - įkvepiamieji milteliai (kietosios kapsulės) - 12 µg - formoterol
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.